AXL and non-small cell lung carcinoma: In AXL gene aberration‐positive NSCLC patients, bemcentinib, an AXL TKI, in combination with pembrolizumab showed significantly improved prognosis and has been granted fast track designation by the U.S. FDA in June 2021 (NCT03184558).